Cargando…
Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort
The aim of the study was to assess RF cross-reactivity to animal antibodies used in immunoassays, and to test if selected commercial immunoassays are vulnerable to interference from RF, causing false test results. Our study included samples from patients with RF-positive rheumatoid arthritis (RA) a...
Autores principales: | Gehin, Johanna E., Klaasen, Rolf A., Norli, Ellen S., Warren, David J., Syversen, Silje W., Goll, Guro L., Bjøro, Trine, Kvien, Tore K., Mjaavatten, Maria D., Bolstad, Nils |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316178/ https://www.ncbi.nlm.nih.gov/pubmed/33944985 http://dx.doi.org/10.1007/s00296-021-04865-9 |
Ejemplares similares
-
Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
por: Gehin, Johanna Elin, et al.
Publicado: (2019) -
Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis
por: Gehin, Johanna Elin, et al.
Publicado: (2021) -
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
por: Gehin, Johanna Elin, et al.
Publicado: (2022) -
Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
por: Brun, Marthe Kirkesæther, et al.
Publicado: (2022) -
A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients
por: Syversen, Silje W, et al.
Publicado: (2008)